NASDAQ:PSNL Personalis (PSNL) Stock Price, News & Analysis $4.88 +0.18 (+3.83%) Closing price 04:00 PM EasternExtended Trading$4.75 -0.13 (-2.64%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Personalis Stock (NASDAQ:PSNL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Personalis alerts:Sign Up Key Stats Today's Range$4.71▼$4.9050-Day Range$4.41▼$7.5652-Week Range$2.83▼$7.79Volume742,397 shsAverage Volume1.06 million shsMarket Capitalization$432.76 millionP/E RatioN/ADividend YieldN/APrice Target$7.42Consensus RatingBuy Company Overview Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California. Read More Personalis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScorePSNL MarketRank™: Personalis scored higher than 83% of companies evaluated by MarketBeat, and ranked 183rd out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPersonalis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePersonalis has only been the subject of 1 research reports in the past 90 days.Read more about Personalis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Personalis are expected to grow in the coming year, from ($1.40) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Personalis is -3.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Personalis is -3.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPersonalis has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Personalis' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.42% of the float of Personalis has been sold short.Short Interest Ratio / Days to CoverPersonalis has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Personalis has recently increased by 4.82%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPersonalis does not currently pay a dividend.Dividend GrowthPersonalis does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-0.66 Percentage of Shares Shorted8.42% of the float of Personalis has been sold short.Short Interest Ratio / Days to CoverPersonalis has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Personalis has recently increased by 4.82%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment1.00 News SentimentPersonalis has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Personalis this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for PSNL on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows2 people have added Personalis to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,181.00 in company stock.Percentage Held by InsidersOnly 3.80% of the stock of Personalis is held by insiders.Percentage Held by Institutions61.91% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Personalis' insider trading history. Receive PSNL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PSNL Stock News HeadlinesPersonalis, Inc. (NASDAQ:PSNL) Receives $7.42 Consensus Target Price from BrokeragesAugust 26 at 2:08 AM | americanbankingnews.comPersonalis gains as VA awards work order worth up to $13.5MAugust 22, 2025 | msn.comTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.August 26 at 2:00 AM | American Alternative (Ad)Personalis Secures New VA Contract Task OrderAugust 22, 2025 | tipranks.comHead to Head Contrast: Personalis (NASDAQ:PSNL) and Teva Pharmaceutical Industries (NYSE:TEVA)August 18, 2025 | americanbankingnews.comAnalyzing Assembly Biosciences (NASDAQ:ASMB) and Personalis (NASDAQ:PSNL)August 17, 2025 | americanbankingnews.comCathie Wood’s ARK Investment buys 133.3K shares of Personalis todayAugust 15, 2025 | msn.comPersonalis, Inc. (NASDAQ:PSNL) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportAugust 8, 2025 | finance.yahoo.comSee More Headlines PSNL Stock Analysis - Frequently Asked Questions How have PSNL shares performed this year? Personalis' stock was trading at $5.78 at the beginning of the year. Since then, PSNL shares have decreased by 16.7% and is now trading at $4.8150. How were Personalis' earnings last quarter? Personalis, Inc. (NASDAQ:PSNL) issued its quarterly earnings data on Tuesday, August, 5th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. The company had revenue of $17.20 million for the quarter, compared to analyst estimates of $20.12 million. Personalis had a negative trailing twelve-month return on equity of 47.57% and a negative net margin of 113.70%. Read the conference call transcript. When did Personalis IPO? Personalis (PSNL) raised $100 million in an initial public offering on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Oppenheimer was co-manager. Who are Personalis' major shareholders? Top institutional shareholders of Personalis include ARK Investment Management LLC (8.05%), AIGH Capital Management LLC (4.22%), Aberdeen Group plc (1.99%) and Blue Water Life Science Advisors LP (1.89%). Insiders that own company stock include Christopher M Hall, Aaron Tachibana, Richard Chen, Stephen Michael Moore and Stephen Michael Moore. View institutional ownership trends. How do I buy shares of Personalis? Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Personalis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Personalis investors own include Digital Turbine (APPS), CrowdStrike (CRWD), Okta (OKTA), Unity Software (U) and Vuzix (VUZI). Company Calendar Last Earnings8/05/2025Today8/26/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - GENERIC DRG Sub-IndustryHealthcare Current SymbolNASDAQ:PSNL CIK1527753 Webwww.personalis.com Phone(650) 752-1300FaxN/AEmployees400Year FoundedN/APrice Target and Rating Average Price Target for Personalis$7.42 High Price Target$9.00 Low Price Target$6.00 Potential Upside/Downside+53.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$81.28 million Net Margins-113.70% Pretax Margin-113.68% Return on Equity-47.57% Return on Assets-35.05% Debt Debt-to-Equity RatioN/A Current Ratio6.09 Quick Ratio5.92 Sales & Book Value Annual Sales$84.61 million Price / Sales5.08 Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book1.69Miscellaneous Outstanding Shares88,680,000Free Float85,307,000Market Cap$429.48 million OptionableOptionable Beta1.86 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:PSNL) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Personalis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Personalis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.